iBio

OverviewSuggest Edit

iBio is a biotechnology company and biologics contract development and manufacturing organization (CDMO). It develops products to treat fibrotic diseases, cancers, and infectious diseases. iBio's platforms and programs include CDMO services using its FastPharming technologies and glycaneering services; the development of therapeutics and vaccines, for which iBio conducts preclinical and clinical trials, and the production of proteins for research and further manufacturing use in 3D-bioprinting and other applications.
TypePublic
Founded2008
HQBryan, TX, US
Websiteibioinc.com
Employee Ratings3.9

Latest Updates

Employees (est.) (Oct 2020)51(-7%)
Job Openings8
Revenue (FY, 2021)$2.4 M(+45%)
Share Price (Jul 2022)$0.2(-4%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at iBio

Thomas F. Isett

Thomas F. Isett

Chief Executive Officer & Chairman of the Board
Martin B. Brenner

Martin B. Brenner

Chief Scientific Officer
Randy J. Maddux

Randy J. Maddux

Chief Operating Officer
Lisa Middlebrook

Lisa Middlebrook

Chief Human Resources Officer
Gary Sender

Gary Sender

Director
Jack Owens

Jack Owens

Director of Quality Assurance
Show more

iBio Office Locations

iBio has an office in Bryan
Bryan, TX, US (HQ)
8800 HSC Pkwy
Show all (1)

iBio Financials and Metrics

iBio Revenue

iBio's revenue was reported to be $2.37 m in FY, 2021
USD

Revenue (Q3, 2022)

1.9m

Gross profit (Q3, 2022)

1.9m

Net income (Q3, 2022)

(12.4m)

EBIT (Q3, 2022)

(12.2m)

Market capitalization (26-Jul-2022)

51.3m

Closing stock price (26-Jul-2022)

0.2

Cash (31-Mar-2022)

33.8m
iBio's current market capitalization is $51.3 m.
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

444.0k2.0m1.6m2.4m

Revenue growth, %

355%(19%)

Cost of goods sold

1.5m

Gross profit

909.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Revenue

45.0k651.0k527.0k108.0k314.0k96.0k410.0k705.0k765.0k211.0k168.0k1.9m

Cost of goods sold

493.0k40.0k113.0k48.0k

Gross profit

272.0k171.0k55.0k1.9m

General and administrative expense

2.9m3.4m2.8m3.0m2.6m3.2m5.6m5.8m5.3m6.6m8.4m8.5m
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Cash

15.9m4.4m55.1m77.4m

Accounts Receivable

75.0k97.0k75.0k426.0k

Prepaid Expenses

276.0k290.0k214.0k2.1m

Inventories

798.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Cash

16.0m13.4m9.0m2.1m3.6m10.0m77.5m91.3m84.6m62.8m39.2m33.8m

Accounts Receivable

119.0k155.0k117.0k75.0k224.0k75.0k300.0k180.0k387.0k207.0k111.0k1.0m

Prepaid Expenses

206.0k396.0k432.0k183.0k146.0k189.0k263.0k1.9m2.5m1.7m2.9m2.3m

Inventories

843.0k1.1m587.0k2.0m3.3m
Annual
USDFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(16.1m)(17.6m)(16.4m)(23.2m)

Depreciation and Amortization

1.7m1.9m2.2m763.0k

Inventories

26.0k(798.0k)

Accounts Payable

49.0k292.0k498.0k48.0k
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022Q2, 2022Q3, 2022

Net Income

(4.4m)(8.9m)(13.1m)(4.5m)(8.2m)(12.9m)(7.5m)(15.7m)(23.3m)(8.9m)(20.9m)(33.2m)

Depreciation and Amortization

443.0k875.0k1.3m558.0k1.1m1.7m584.0k1.2m548.0k394.0k1.0m1.9m

Inventories

(45.0k)(273.0k)

Accounts Payable

(16.0k)(40.0k)(29.0k)(403.0k)(549.0k)(440.0k)(12.0k)491.0k(303.0k)79.0k872.0k1.6m
USDFY, 2018

Revenue/Employee

10.3k

Debt/Equity

1.6 x

Debt/Assets

0.6 x

Financial Leverage

2.7 x
Show all financial metrics

iBio Operating Metrics

FY, 2016

Patents Issued

67

Patents Pending

19

iBio Revenue Breakdown

Embed Graph

iBio revenue breakdown by business segment: 94.4% from iBio, Inc. and 5.6% from iBio CDMO

iBio Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

iBio Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

iBio Online and Social Media Presence

Embed Graph

iBio News and Updates

iBio to Participate in the H.C. Wainwright Global Investment Conference

BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System, today announced that it will participate virtually in the H.C. Wainwri…

iBio to Report Fiscal 2022 Third Quarter Financial Results and Provide Corporate Update on Thursday, May 12, 2022

BRYAN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 third quarter fina…

iBio Announces Presentation Highlighting Superior Glycosylation for Antibodies Produced in Plants

Data Showing Greater Glycosylation Homogeneity with the FastPharming® System Compared to Traditional Methods to be Presented at PEGS Conference & Expo

iBio to Participate in the Oppenheimer 32nd Annual Healthcare Conference

BRYAN, Texas, March 11, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that its Chairman & CEO, Tom Isett, will present…

iBio Reports Fiscal Second Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, Feb. 14, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming Manufacturing System®, today announces its financial results for the fiscal quarter ended December 31, 20…

iBio to Report Fiscal 2022 Second Quarter Financial Results and Provide Corporate Update on Monday, February 14, 2022

BRYAN, Texas, Feb. 07, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it will report its fiscal 2022 second quarter fi…
Show more

iBio Blogs

Using the Power of Plants to Develop Novel Biopharmaceuticals

Biologics manufacturing company iBio is using plants as bioreactors to develop and manufacture therapeutics and vaccines with the goal of eliminating the significant cost and time associated with selecting, developing, and banking mammalian cell lines. The post Using the Power of Plants to Develop N…

iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceutic…

Changing the Paradigm of Cancer Drug Discovery and Development with Plants

In this article, iBio’s Chief Scientific Officer, Martin Brenner, DVM, Ph.D.; Chief Operating Officer, Randy Maddux; and oncology pipeline advisor, Steven King, explore how the iBio Drug Discovery Center is using the FastPharming System® to support faster and more efficient development of powerful n…

Plant-Based Biologics With iBio’s Randy Maddux

iBio COO Randy Maddux walks us through the Bryan, Texas-based biopharma’s attempt to turn the CHO cell biologic development paradigm on its ear with hydroponically-grown N. benthamiana. His company’s FastPharming approach to protein production, he says, could be modularized to speed cycle times and …

Vaccine Manufacturing: Chasing COVID’s Long Tail

By Mid-December 2021, the RAPS (Regulatory Affairs Professionals Society) COVID-19 Vaccine Tracker listed 91 active COVID-19 candidates in development around the globe. That’s in addition to the 25 vaccine products already approved by various international regulatory authorities. Just months ago, on…

iBio Establishes Oncology Drug Discovery Pipeline with Three New Antibody Programs

BRYAN, Texas, July 08, 2021 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, has taken another major step towards leveraging the speed and throughput of its proprietary, plant-based FastPharming Protein Expre…
Show more

iBio Frequently Asked Questions

  • When was iBio founded?

    iBio was founded in 2008.

  • Who are iBio key executives?

    iBio's key executives are Thomas F. Isett, Martin B. Brenner and Randy J. Maddux.

  • How many employees does iBio have?

    iBio has 51 employees.

  • What is iBio revenue?

    Latest iBio annual revenue is $2.4 m.

  • What is iBio revenue per employee?

    Latest iBio revenue per employee is $46.5 k.

  • Who are iBio competitors?

    Competitors of iBio include Alvotech, Tedor Pharma and KBI Biopharma.

  • Where is iBio headquarters?

    iBio headquarters is located at 8800 HSC Pkwy, Bryan.

  • Where are iBio offices?

    iBio has an office in Bryan.

  • How many offices does iBio have?

    iBio has 1 office.